Development of Hypothyroidism with Thyroid Stimulation Blocking Antibody long after Treatment with Antithyroid Drugs in a Patient with Hyperthyroid Graves' Disease: A Case Report.

Abstract

Abstract. We observed a patient manifesting spontaneous hypothyroidism with thyroid stimulation blocking antibody (TSBAb) long after treatment with antithyroid drugs (ATDs) for hyperthyroid Graves' disease. A 19-year-old female with Graves' disease was treated with ATDs for approximately 2 years; after cessation of ATDs, hyperthyroidism did not recur. Nine years later, she was again seen in our hospital because of symptoms indicative of hypothyroidism. Thyroid hormone replacement was commenced after laboratory confirmation of hypothyroidism. TSH-binding inhibitor immunoglobulin and TSBAb were both positive, while thyroid stimulating antibody (TSAb) was negative, at the time of diagnosis of hypothyroidism. These results indicated that the alterations in thyroid function in this patient appeared to relate to the presumed decline in the activity of TSAb and the appearance of TSBAb years after ATDs administration had been discontinued.

Impact of caloric restriction on health and survival in rhesus monkeys from the NIA study

“…CR initiated in the youngest male monkeys delayed maturation 36 and slowed skeletal growth 37 . Additionally, the immune response of only the adolescent males was improved by CR 13 .…”

Similar Clinical Performance of a Novel Chimeric Thyroid-Stimulating Hormone Receptor Bioassay and an Automated Thyroid-Stimulating Hormone Receptor Binding Assay in Graves' Disease

“…Using porcine thyroid cell cAMP system (5), TSBAb activity was assayed by measuring the ability of patients' immunoglobulin G (IgG) to inhibit TSH-stimulating cAMP production in comparison to control IgG response and was calculated as follows (11,12):…”